What's New in Psoriasis Treatment: 2026 Research Roundup
Biologics targeting IL-17 and IL-23, next-gen topicals, and combination therapies are reshaping psoriasis care. Here is what the latest research shows.
Get research like this in your inbox — free
IL-23 Inhibitors: Long-Term Data Looks Strong
Interleukin-23 (IL-23) inhibitors have become a cornerstone of moderate-to-severe psoriasis treatment, and 2026 is delivering important long-term data. Extended follow-up studies published this year show that drugs in this class maintain high rates of skin clearance (PASI 90 and PASI 100 responses) out to 4 and 5 years, with consistent safety profiles.
What is particularly noteworthy is the dosing convenience. Research confirms that after initial loading doses, many IL-23 inhibitors require injections only every 8 to 12 weeks, which studies show improves patient adherence compared to more frequent dosing schedules. A 2026 comparative effectiveness study found that IL-23 inhibitors matched or exceeded the efficacy of IL-17 inhibitors for most patients, with potentially fewer candida infections.
Researchers are also studying whether IL-23 inhibitors can achieve "drug-free remission" in some patients. A provocative 2026 study found that a subset of patients who achieved complete clearance could discontinue treatment and maintain remission for extended periods, suggesting that these drugs may actually modify the disease course rather than just suppressing symptoms.
What this means for you: If you have moderate-to-severe psoriasis, research suggests IL-23 inhibitors offer effective, convenient, long-term control with a good safety profile. If you are interested in the latest biologic options, discuss them with your dermatologist.
IL-17 Inhibitors: Expanding Applications
IL-17 inhibitors continue to be refined in 2026. New research focuses on bimekizumab, which targets both IL-17A and IL-17F. Studies published this year show that this dual-targeting approach achieves very high clearance rates, with some trials reporting PASI 100 responses in over 60% of patients.
Research is also expanding the use of IL-17 inhibitors beyond skin symptoms. Studies in 2026 are examining their effectiveness for psoriatic arthritis, nail psoriasis, and scalp psoriasis specifically, with encouraging results across all three areas. A real-world evidence study found that patients with both joint and skin involvement benefited significantly from IL-17 inhibitors as a single treatment addressing multiple disease manifestations.
What this means for you: If psoriasis affects your joints, nails, or scalp in addition to your skin, studies suggest that newer IL-17 inhibitors may address multiple symptoms with one medication. Talk to your dermatologist about whether this approach could simplify your treatment.
Topical Advances: New Options for Mild-to-Moderate Disease
Not everyone with psoriasis needs a biologic, and 2026 research is also improving topical treatment options. Studies on newer topical formulations, including tapinarof (an aryl hydrocarbon receptor agonist) and roflumilast (a PDE4 inhibitor cream), continue to show good results for mild-to-moderate plaques.
A 2026 comparative trial found that tapinarof cream achieved significant improvements in affected body surface area without the skin thinning associated with long-term topical corticosteroid use, making it an appealing option for sensitive areas like the face and skin folds.
Research on combination topical approaches is also advancing. Studies suggest that pairing these newer agents with traditional vitamin D analogues may produce better results than either alone, with acceptable side-effect profiles.
What this means for you: If you have mild-to-moderate psoriasis or want to reduce your steroid use, newer topical options are showing promise in research. Ask your dermatologist about recently approved topicals and whether they might work for your specific plaques.
The Bigger Picture: Comorbidity Management
An important thread in 2026 psoriasis research is the growing understanding of systemic inflammation and comorbidities. Studies are finding that effective psoriasis treatment may also reduce cardiovascular risk markers, with biologic-treated patients showing improvements in arterial inflammation measured by imaging studies.
Want to stay updated on psoriasis research? Sign up for free alerts and get plain-English summaries delivered to your inbox.
This article summarizes published research and is not medical advice. Discuss any findings with your healthcare provider before making decisions about your care. Content is generated with AI assistance and reviewed for accuracy.